Disseminated growth of murine plasmacytoma: Similarities to multiple myeloma

Cancer Research

Volumn 58, Issue 3, 1998, Pages 535-541

  Roschke, Viktor ^a   Hausner, Petr ^a   Kopantzev, Eugene ^a   Pumphrey, Janet G ^a   Riminucci, Mara ^b   Hilbert, David M ^a   Rudikoff, Stuart ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW METASTASIS; CONTROLLED STUDY; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PHENOTYPE; PLASMACYTOMA; PRIORITY JOURNAL; SPLEEN; TUMOR CELL LINE; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 0032005941     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Merwin, R. M., and Algire, G. H. Induction of plasma cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers. Proc. Soc. Exp. Biol. Med., 101: 437-439, 1959.
2. Potter, M., and Boyce, C. Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature (Lond.), 193: 1086-1087, 1962.
3. Potter, M., and Wax, J. S. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J. Natl. Cancer Inst., 71: 391-395, 1983.
4. Potter, M., Morrison, S., Wiener, F., Zhang, X. K., and Miller, F. W. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. J. Natl. Cancer Inst., 86: 1058-1065, 1994.
5. Degrassi, A., Hilbert, D. M., Rudikoff, S., Anderson, A. O., Potter, M., and Coon, H. G. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc. Natl. Acad. Sci. USA, 90: 2060-2064, 1993.
6. Kopantzev, E., Roschke, V., and Rudikoff, S. IL-2 mediated modulation of plasma cell tumor growth in a model of multiple myeloma. Hum. Gene Ther., in press, 1997.
7. Hawkins, R. E., and Winter, G. Cell selection strategies for making antibodies from variable gene libraries: trapping the memory pool. Eur. J. Immunol., 22: 867-870, 1992.
8. Pumphrey, J. G., Hausner, P., and Rudikoff, S. Characterization of C57BL/6 plasmacytomas lacking a c-myc translocation. Int. J. Cancer, 72: 892-897, 1997.
9. Joshua, D. E., and Gibson, J. Diagnosis and treatment of multiple myeloma. In: P. H. Wiernik, G. P. Canellos, J. P. Dutcher, and R. A. Kyle (eds.), Neoplastic Diseases of the Blood, pp. 561-583. New York: Churchill Livingstone, 1996.
10. Hilbert, D. M., Shen, M. Y., Rapp, U. R., and Rudikoff, S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc. Natl. Acad. Sci. USA, 92: 649-655, 1995.
11. Kubagawa, H., Vogler, L. B., Capra, J. D., Conrad, M. E., Lawton, A. R., and Cooper, M. D. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J. Exp. Med., 150: 792-807, 1979.
12. Billadeau, D., Ahmann, G., Greipp, P., and Van Ness, B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med., 178: 1023-1031, 1993.
13. Corradini, P., Boccadoro, M., Voena, C., and Pileri, A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)-and IgA-secreting multiple myelomas. J. Exp. Med., 178: 1091-1096, 1993.
14. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., and Tanaka, H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83-85, 1988.
15. Bergui, L., Schena, M., Gaidano, G., Riva, M., and Caligaris-Cappio, F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med., 170: 613-618, 1989.
16. Hitzler, J. K., Martinez-Valdez, H., Bergsagel, D. B., Minden, M. D., and Messner, H. A. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood, 78: 1996-2004, 1991.
17. Zhang, X. G., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., and Klein, B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood, 83: 3654-3663, 1994.
18. Hilbert, D. M., Kopf, M., Mock, B. A., Kohler, G., and Rudikoff, S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med., 182: 243-248, 1995.
19. Hilbert, D. M., Migone, T. S., Kopf, M., Leonard, W. J., and Rudikoff, S. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity, 5: 81-89, 1996.
20. Hayes, D. W., Bennett, W. A., and Heck, F. J. Extramedullary lesions in multiple myeloma. Arch. Pathol., 53: 262-272, 1952.
21. Kapadia, S. B. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine, 59: 380-392, 1980.
22. MacLennan, I. C., Drayson, M., and Dunn, J. Multiple myeloma. Br. Med. J., 308: 1033-1036, 1994.
23. Feo-Zuppardi, F. J., Taylor, C. W., Iwato, K., Lopez, M. H., Grogan, T. M., Odeleye, A., Hersh, E. M., and Salmon, S. E. Long-term engraftment of fresh human myeloma cells in SCID mice. Blood, 80: 2843-2850, 1992.
24. Bellamy, W. T., Odeleye, A., Finley, P., Huizenga, B., Dalton, W. S., Weinstein, R. S., Hersh, E. M., and Grogan, T. M. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am. J. Pathol., 142: 691-698, 1993.
25. Huang, Y. W., Richardson, J. A., Tong, A. W., Zhang, B. Q., Stone, M. J., and Vitetta, E. S. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res., 53: 1392-1396, 1993.
26. Alsina, M., Boyce, B. F., Mundy, G. R., and Roodman, G. D. An in vivo model of human multiple myeloma bone disease. Stem Cells (Dayton), 13 (Suppl. 2): 48-50, 1995.
27. Alsina, M., Boyce, B., Devlin, R. D., Anderson, J. L., Craig, F., Mundy, G. R., and Roodman, G. D. Development of an in vivo model of human multiple myeloma bone disease. Blood, 87: 1495-1501, 1996.
28. Bellamy, W. T., Mendibles, P., Bontje, P., Thompson, F., Richter, L., Weinstein, R. S., and Grogan, T. M. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype. Cancer Chemother. Pharmacol., 37: 305-316, 1996.
29. Croese, J. W., Vas Nunes, C. M., Radl, J., Van den Enden-Vieveen, M. H., Brondijk, R. J., and Boersma, W. J. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br. J. Cancer, 56: 555-560, 1987.
30. Radl, J., Punt, Y. A., Van den Enden-Vieveen, M. H., Bentvelzen, P. A., Bakkus, M. H., van den Akker, T. W., and Benner, R. The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations. Br. J. Cancer, 61: 276-278, 1990.